[go: up one dir, main page]

CU24735B1 - Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 - Google Patents

Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2

Info

Publication number
CU24735B1
CU24735B1 CU2022000064A CU20220064A CU24735B1 CU 24735 B1 CU24735 B1 CU 24735B1 CU 2022000064 A CU2022000064 A CU 2022000064A CU 20220064 A CU20220064 A CU 20220064A CU 24735 B1 CU24735 B1 CU 24735B1
Authority
CU
Cuba
Prior art keywords
agonists
heterocyclic compounds
myeloid cells
receptor expressed
activation receptor
Prior art date
Application number
CU2022000064A
Other languages
English (en)
Other versions
CU20220064A7 (es
Inventor
Maxence Bos
Lara C Czabaniuk
Ivan Franzoni
Timothy Hopper
Jonathan B Houze
John Mancuso
Jane Panteleev
Gwenaella Rescourio
Vincent Santora
Haoxuan Wang
Ryan D White
Alice R Wong
Yongwei Wu
Original Assignee
Amgen Inc
Vigil Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Vigil Neuroscience Inc filed Critical Amgen Inc
Publication of CU20220064A7 publication Critical patent/CU20220064A7/es
Publication of CU24735B1 publication Critical patent/CU24735B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción proporciona compuestos de la Fórmula I, útiles para la activación del receptor de activación expresado en células mieloides 2 ("TREM2").</p> <p>ESPACIO PARA FÓRMULA</p> <p> Además, la descripción proporciona productos intermedios útiles en la síntesis de compuestos de la Fórmula I.<br /> </p>
CU2022000064A 2020-05-04 2021-05-04 Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 CU24735B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063019772P 2020-05-04 2020-05-04
PCT/US2021/070507 WO2021226629A1 (en) 2020-05-04 2021-05-04 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use

Publications (2)

Publication Number Publication Date
CU20220064A7 CU20220064A7 (es) 2023-06-13
CU24735B1 true CU24735B1 (es) 2025-02-07

Family

ID=78468522

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000064A CU24735B1 (es) 2020-05-04 2021-05-04 Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2

Country Status (20)

Country Link
US (4) US11608344B2 (es)
EP (1) EP4146222A4 (es)
JP (2) JP7754846B2 (es)
KR (1) KR20230019822A (es)
CN (1) CN115867284A (es)
AR (1) AR122010A1 (es)
AU (1) AU2021266805A1 (es)
BR (1) BR112022022341A2 (es)
CA (1) CA3182105A1 (es)
CL (1) CL2022003047A1 (es)
CO (1) CO2022015930A2 (es)
CR (1) CR20220560A (es)
CU (1) CU24735B1 (es)
EC (1) ECSP22089527A (es)
IL (1) IL297833A (es)
MX (1) MX2022013842A (es)
PE (1) PE20230846A1 (es)
PH (1) PH12022552949A1 (es)
TW (1) TW202208355A (es)
WO (1) WO2021226629A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182541A1 (en) 2020-05-04 2021-11-11 Amgen Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
MX2023006397A (es) * 2020-12-04 2023-08-11 Vigil Neuroscience Inc Tratamiento de enfermedades relacionadas con disfunción del transportador 1 del casete de unión a atp utilizando agonistas trem2.
AU2022269034A1 (en) * 2021-05-04 2023-11-16 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
EP4430029A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 AND METHODS OF USE
EP4430022A4 (en) * 2021-11-09 2025-09-10 Vigil Neuroscience Inc HETEROCYCLIC COMPOUNDS USED AS AGONISTS OF THE TRIGGER RECEPTOR EXPRESSED ON MYELOID CELLS 2 AND METHODS OF USE
WO2023086799A1 (en) * 2021-11-09 2023-05-19 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists
US20250215077A1 (en) * 2022-03-28 2025-07-03 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024233848A1 (en) * 2023-05-10 2024-11-14 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2025017059A1 (en) * 2023-07-17 2025-01-23 Muna Therapeutics Aps Trem2 modulators
WO2025128848A1 (en) * 2023-12-12 2025-06-19 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
WO2025146475A1 (en) 2024-01-04 2025-07-10 Muna Therapeutics Aps Trem2 modulators
US12459952B2 (en) 2024-01-04 2025-11-04 Muna Therapeutics Aps TREM2 modulators
WO2025157993A1 (en) * 2024-01-24 2025-07-31 Muna Therapeutics Aps Trem2 modulators

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US2963481A (en) 1959-11-27 1960-12-06 Smith Kline French Lab 6-pteridinecarboxylic acid esters
US3712892A (en) 1969-08-02 1973-01-23 Sumitomo Chemical Co Quinazolinone derivatives
JPH05170744A (ja) * 1991-12-25 1993-07-09 Toray Dow Corning Silicone Co Ltd 含窒素芳香族複素環式化合物のアルキル化方法
WO1995018616A2 (en) 1994-01-03 1995-07-13 Acea Pharm Inc 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
DE69814135T2 (de) 1997-10-28 2004-04-01 Warner-Lambert Co. Llc 7-substituierte chinazolin-2,4-dionen verwendbar als antibakterielle mittel
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
JP2004521892A (ja) 2000-12-20 2004-07-22 メルク　エンド　カムパニー　インコーポレーテッド （ハロ−ベンゾカルボニル）複素環縮合フェニル系ｐ３８キナーゼ阻害剤
JP2003005355A (ja) 2001-06-20 2003-01-08 Fuji Photo Film Co Ltd 電子線又はｘ線用ネガ型レジスト組成物
CA2500952C (en) 2002-10-04 2011-04-26 Prana Biotechnology Limited Neurologically-active compounds
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
AU2004283479A1 (en) 2003-10-17 2005-05-06 4 Aza Bioscience Nv Heterocycle-substituted pteridine derivatives and their use in therapy
WO2005042501A1 (en) 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
RU2358969C2 (ru) 2004-02-13 2009-06-20 Баниу Фармасьютикал Ко., Лтд. Конденсированное 4-оксопиримидиновое производное
WO2005087742A1 (en) * 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
US8084459B2 (en) 2004-04-02 2011-12-27 Prana Biotechnology Ltd Substituted quinazolinones for treating neurological conditions
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
AU2006217744A1 (en) * 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited 2,4-diamino-pyridopyrimidine derivatives and their use as MTOR inhibitors
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
KR100659088B1 (ko) 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
US20080261974A1 (en) 2005-09-23 2008-10-23 Kevin J Duffy Novel Chemical Compounds
US20090082349A1 (en) 2006-03-02 2009-03-26 Dashyant Dhanak Thiazolones for use as pi3 kinase inhibitors
US7855194B2 (en) 2006-03-27 2010-12-21 Hoffmann-La Roche Inc. Pyrimidine, quinazoline, pteridine and triazine derivatives
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
BRPI0715888B1 (pt) 2006-08-23 2021-11-03 Kudos Pharmaceuticals Limited Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
AU2008241483B2 (en) 2007-04-18 2011-03-24 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
US20090099195A1 (en) * 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
JP2011500657A (ja) 2007-10-15 2011-01-06 アストラゼネカ アクチボラグ 組合せ０５９
WO2009100406A2 (en) 2008-02-07 2009-08-13 Synta Pharmaceuticals Corp. Topical formulations for the treatment of psoriasis
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
WO2010033906A2 (en) 2008-09-19 2010-03-25 President And Fellows Of Harvard College Efficient induction of pluripotent stem cells using small molecule compounds
EP3135672B9 (en) 2008-10-10 2020-05-20 VM Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN102574847A (zh) 2009-07-30 2012-07-11 Irm责任有限公司 作为syk激酶抑制剂的化合物和组合物
WO2011014039A1 (en) 2009-07-31 2011-02-03 Rohm And Haas Electronic Materials Korea Ltd. Novel organic electroluminescent compounds and organic electroluminescent device using the same
WO2011037731A1 (en) 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
MX2012004846A (es) 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
ES2586227T3 (es) 2010-03-16 2016-10-13 Merck Patent Gmbh Morfolinilquinazolinas
WO2011156889A1 (en) 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
SG10201604497UA (en) * 2011-06-02 2016-07-28 Almac Diagnostics Ltd Molecular Diagnostic Test For Cancer
CN102887895B (zh) 2011-07-22 2016-08-24 山东轩竹医药科技有限公司 吡啶并嘧啶类mTOR抑制剂
KR101497124B1 (ko) 2011-11-28 2015-03-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 포함하는 유기전기소자 및 그 전자 장치
MY169159A (en) 2012-02-08 2019-02-19 Janssen R&D Ireland Piperidino-pyrimidine derivatives for the treatment of viral infections
CN103374021B (zh) 2012-04-21 2015-10-28 通化济达医药有限公司 含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
JP6192836B2 (ja) 2013-07-30 2017-09-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒｃモジュレーターとしてのアザインドール化合物
US9815797B2 (en) 2013-12-09 2017-11-14 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of TNF activity
KR20150080966A (ko) 2014-01-02 2015-07-13 최돈수 유기 전기 발광 소자용 발광 재료, 이를 이용한 유기 전기 발광 소자 및 유기 전기 발광 소자용 재료
KR20160060572A (ko) 2014-11-19 2016-05-30 주식회사 엠비케이 유기 발광 화합물, 잉크 조성물, 유기 발광 소자 및 전자 기기
AU2016248886B2 (en) 2015-04-15 2020-09-10 F. Hoffmann-La Roche Ag Pyridopyrimidinones and their use as NMDA receptor modulators
US10403826B2 (en) 2015-05-07 2019-09-03 Universal Display Corporation Organic electroluminescent materials and devices
WO2017025164A1 (de) 2015-08-11 2017-02-16 Merck Patent Gmbh Materialien für organische elektrolumineszenzvorrichtungen
WO2017031427A1 (en) 2015-08-19 2017-02-23 3-V Biosciences, Inc. COMPOUNDS AND METHODS FOR INHIBITING mTOR
KR102606277B1 (ko) 2016-04-06 2023-11-27 삼성디스플레이 주식회사 유기 발광 소자
US10573692B2 (en) 2016-04-06 2020-02-25 Samsung Display Co., Ltd. Organic light-emitting device having a sealing thin film encapsulation portion
EP3442947B1 (en) 2016-04-15 2023-06-07 Epizyme, Inc. Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US11283028B2 (en) 2016-10-05 2022-03-22 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent compound and organic electroluminescent device comprising the same
CN109790183A (zh) 2016-12-13 2019-05-21 广州华睿光电材料有限公司 金属有机配合物及其应用、混合物、有机电子器件
GB201700814D0 (en) * 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
TW201843143A (zh) 2017-03-13 2018-12-16 德商麥克專利有限公司 含有芳基胺結構之化合物
WO2018169352A1 (en) 2017-03-16 2018-09-20 Rohm And Haas Electronic Materials Korea Ltd. Organic electroluminescent device
KR102335935B1 (ko) 2017-03-22 2021-12-06 덕산네오룩스 주식회사 유기전기소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US20200113901A1 (en) 2017-03-31 2020-04-16 Epizyme, Inc. Methods of using ehmt2 inhibitors
KR102389204B1 (ko) 2017-04-18 2022-04-21 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
CN110996945A (zh) 2017-06-13 2020-04-10 联邦科学技术研究组织 抗病毒药物
JPWO2019065516A1 (ja) 2017-09-26 2020-09-10 日本曹達株式会社 キノリン化合物および農園芸用殺菌剤
CA3079412A1 (en) 2017-10-18 2019-04-25 Epizyme, Inc. Methods of using ehmt2 inhibitors in immunotherapies
WO2019079607A1 (en) 2017-10-18 2019-04-25 Epizyme, Inc. METHODS OF USING EHMT2 INHIBITORS IN THE TREATMENT OR PREVENTION OF BLOOD DISORDERS
CN108484680B (zh) 2018-01-31 2020-12-11 马鞍山南京大学高新技术研究院 一类双硫代芳环/芳杂环磷酸化合物作为辅助配体的铱配合物
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
US12453279B2 (en) 2018-08-22 2025-10-21 Universal Display Corporation Organic electroluminescent materials and devices
CN109265457A (zh) 2018-11-01 2019-01-25 中国药科大学 一种利用氧化芳构化构建吡啶并嘧啶二酮骨架的新方法
WO2020231739A2 (en) 2019-05-10 2020-11-19 Antidote Ip Holdings, Llc Compounds and methods for treating cancer
CN110283171A (zh) 2019-07-17 2019-09-27 鼎泰(南京)临床医学研究有限公司 一类含有吡啶并嘧啶-4-胺类结构的化合物、药物组合物以及其应用
US11820783B2 (en) 2019-09-06 2023-11-21 Universal Display Corporation Organic electroluminescent materials and devices
CR20220610A (es) 2020-05-04 2023-01-10 Adama Makhteshim Ltd Mezclas y composiciones que comprenden 5-fluoro-4-imino-3-metil-1-tosil-3,4-dihidropirimidin-2-ona, y métodos de uso de las mismas
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CA3182541A1 (en) 2020-05-04 2021-11-11 Amgen Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
BR112022022184A2 (pt) 2020-05-04 2023-01-17 Takeda Pharmaceuticals Co Derivados de n-(piperidin-4-il)benzamida agindo luminalmente
CN111454265B (zh) 2020-05-07 2021-08-24 宁波卢米蓝新材料有限公司 一种稠杂环化合物及其制备方法和应用
US20230287422A1 (en) 2022-01-11 2023-09-14 Regeneron Pharmaceuticals, Inc. Triggering Receptor Expressed On Myeloid Cells 2 (TREM2) Variants And Uses Thereof

Also Published As

Publication number Publication date
JP2026004465A (ja) 2026-01-14
CL2022003047A1 (es) 2023-07-14
EP4146222A1 (en) 2023-03-15
CA3182105A1 (en) 2021-11-11
CO2022015930A2 (es) 2023-01-26
KR20230019822A (ko) 2023-02-09
US20230295170A1 (en) 2023-09-21
US11884675B2 (en) 2024-01-30
MX2022013842A (es) 2023-02-22
TW202208355A (zh) 2022-03-01
ECSP22089527A (es) 2023-02-28
US12428425B2 (en) 2025-09-30
EP4146222A4 (en) 2024-10-09
CU20220064A7 (es) 2023-06-13
US20230002390A1 (en) 2023-01-05
WO2021226629A1 (en) 2021-11-11
CN115867284A (zh) 2023-03-28
JP7754846B2 (ja) 2025-10-15
US11608344B2 (en) 2023-03-21
US11912711B2 (en) 2024-02-27
AR122010A1 (es) 2022-08-03
US20240182477A1 (en) 2024-06-06
BR112022022341A2 (pt) 2023-01-10
PE20230846A1 (es) 2023-05-23
AU2021266805A1 (en) 2022-12-01
US20230295169A1 (en) 2023-09-21
JP2023525035A (ja) 2023-06-14
CR20220560A (es) 2023-08-18
IL297833A (en) 2023-01-01
PH12022552949A1 (en) 2024-02-12

Similar Documents

Publication Publication Date Title
CU24735B1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CU20220065A7 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
ECSP109987A (es) Métodos y compuestos útiles para preparar inhibidores del co-transportador 2 sodio glucosa
PE20160113A1 (es) Procesos de fabricacion y formas cristalinas de un inhibidor de mdm2
ECSP11011244A (es) Nuevos herbicidas.
NI200900213A (es) Pirazol amidas de ácido carboxílico útiles como microbicidas.
UY30292A1 (es) Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico
CO6440524A2 (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus.
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
PE20090964A1 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de proteina quinasa b
AR050407A1 (es) Compuestos quinolinon-carboxamida como agonistas del receptor 5-ht4. procesos de obtencion y composiciones farmaceuticas
SV2010003475A (es) Nuevos herbicidas
MX2023012901A (es) Compuestos heterocíclicos como agonistas del receptor de activacion expresado en las células mieloides 2 y métodos de uso.
CY1124329T1 (el) N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
UY30640A1 (es) Compuestos
CR9670A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
ECSP088383A (es) Tetrahidroquinolinas, su síntesis e intermediarios campo de la invención
ECSP099702A (es) Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2
ECSP088251A (es) Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
CU20090131A7 (es) Nuevo proceso de síntesis industrial de agomelatina
HN2009001441A (es) Compuestos de 2- aminopirimidina como potentes inhibidores de hsp-90
DOP2003000587A (es) AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
PE20070084A1 (es) Proceso para la sintesis de 5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-bencenamina
AR127622A1 (es) Compuestos heterocíclicos como agonistas del receptor activador expresado en células mieloides 2 y métodos de uso